Literature DB >> 3275895

Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes mellitus.

R C Ramsay1, F C Goetz, D E Sutherland, S M Mauer, L L Robison, H L Cantrill, W H Knobloch, J S Najarian.   

Abstract

We studied the effect of successful pancreas transplantation and consequent normoglycemia (mean total hemoglobin A1, 7.0 percent; range, 5.8 to 8.3) on visual function and diabetic retinopathy in 22 patients with Type I diabetes mellitus (study group). Sixteen similar patients in whom pancreas transplantation had been unsuccessful (mean total hemoglobin A1, 12.0 percent; range, 8.0 to 18.0) served as a control group. The majority of patients in both groups had advanced proliferative retinopathy. At a mean follow-up of 24 months we found no significant difference between the groups in the rate of progression of retinopathy, expressed as a score. Success of the transplantation did not prevent progression of retinopathy across the range of retinopathy studied. Progressive retinopathy was observed more commonly in patients with low retinopathy scores (nonproliferative or mild proliferative retinopathy) at base line in both the study group (13 of 17 eyes, or 76 percent) and the control group (7 of 12 eyes, or 58 percent). Further analysis suggested the possibility that after three years of euglycemia, the study group had less deterioration than the control group, particularly in eyes with advanced retinopathy. We observed no difference in the rate of loss of vision between the two groups. This study provides evidence that pancreas transplantation and subsequent normoglycemia neither reverse nor prevent the progression of diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3275895     DOI: 10.1056/NEJM198801283180403

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  57 in total

Review 1.  Surgical treatment of diabetes mellitus by islet cell and pancreas transplantation.

Authors:  S A White; R Kimber; P S Veitch; M L Nicholson
Journal:  Postgrad Med J       Date:  2001-06       Impact factor: 2.401

Review 2.  Pancreatic transplantation: why, when and who?

Authors:  P J Lefèbvre
Journal:  Diabetologia       Date:  1992-05       Impact factor: 10.122

3.  Decay of haemoglobin A1c upon return to normoglycaemia.

Authors:  E Chantelau
Journal:  Diabetologia       Date:  1992-02       Impact factor: 10.122

4.  Visual improvement after long-term success of pancreatic transplantation.

Authors:  T R Friberg; A G Tzakis; P B Carroll; T E Starzl
Journal:  Am J Ophthalmol       Date:  1990-11-15       Impact factor: 5.258

5.  Coming of age for pancreas transplantation.

Authors:  D E Sutherland
Journal:  West J Med       Date:  1989-03

6.  Long-term global retinal microvascular changes in a transgenic vascular endothelial growth factor mouse model.

Authors:  W-Y Shen; C M Lai; C E Graham; N Binz; Y K Y Lai; J Eade; D Guidolin; D Ribatti; S A Dunlop; P E Rakoczy
Journal:  Diabetologia       Date:  2006-05-10       Impact factor: 10.122

Review 7.  Pancreas transplantation: indications and outcomes.

Authors:  D E Sutherland
Journal:  Acta Diabetol       Date:  1992       Impact factor: 4.280

Review 8.  Transplantation for type 1 diabetes: whole organ pancreas and islet cells.

Authors:  Martha Pavlakis; Khalid Khwaja
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

Review 9.  Recent developments in insulin delivery techniques. Current status and future potential.

Authors:  F P Kennedy
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

10.  Transplantation for type I diabetes: comparison of vascularized whole-organ pancreas with isolated pancreatic islets.

Authors:  Adam Frank; Shaoping Deng; Xiaolun Huang; Ergun Velidedeoglu; Yong-Suk Bae; Chengyang Liu; Peter Abt; Robert Stephenson; Muhammad Mohiuddin; Thav Thambipillai; Eileen Markmann; Maral Palanjian; Marty Sellers; Ali Naji; Clyde F Barker; James F Markmann
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.